Search

Clinical Research

C001

OVEREXPRESSION OF HOMOLOGOUS REPAIR PROTEINS IN HUMAN PAPILLOMAVIRUS POSITIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA BY IMMUNOHISTOCHEMISTRY ANALYSIS. A POTENTIAL TARGET FOR MOLECULAR THERAPIES.

Immunotherapy and Other Adjuvant Treatments

Andrew J Holcomb, MD1, Sufi Thomas, PhD1, Yelizaveta Shnayder, MD1, Rashna Madan, MD1, Ossama Tawfik, MD, PhD1, Nicholas Wallace, PhD2

1University of Kansas Medical Center, 2Kansas State University


C002

DEFINED GENETIC ALTERATIONS AS A BIOMARKER PREDICTING PROGNOSIS IN HPV-ASSOCIATED HEAD AND NECK CANCER.

Immunotherapy and Other Adjuvant Treatments

Andrew B Sewell, MD, Michael Hajek, MD, Cassie Pan, BS, Tejas Sather, BS, Wendell G Yarbrough, MD, MMHC, Natalia Issaeva, PhD

Yale University


C003

PLASMACYTOID DENDRITIC CELLS ARE DISTINCTLY IMMUNOSTIMULATORY IN HPV-POSITIVE HNSCC

Immunotherapy and Other Adjuvant Treatments

Kate Poropatich, Sandeep Samant, Bin Zhang

Northwestern University


C004

HIGH THROUGHPUT DRUG TESTING IDENTIFIES AGENTS WITH SELECTIVE ACTIVITY IN HPV-POSITIVE AND HPV-NEGATIVE CELL LINES

Immunotherapy and Other Adjuvant Treatments

Farhad Ghasemi, BSc1, Morgan D Black, BSc, MSc1, Alessandro Datti, PhD2, John W Barrett, PhD1, John Yoo, MD1, Kevin Fung, MD1, S D MacNeil, MD, MSc1, Anthony C Nichols, MD1

1Western University, 2Lunenfeld Tanenbaum Research Institute


AHNS013

ADJUVANT RADIATION FOR POSITIVE MARGINS IN ADULT H&N SARCOMAS IS ASSOCIATED WITH IMPROVED SURVIVAL: ANALYSIS OF THE NATIONAL CANCER DATABASE

Immunotherapy and Other Adjuvant Treatments

Richard B Cannon, MD, Patrick Carpenter, MD, Amanda J Kull, MD, Sam Francis, MD, Luke O Buchmann, MD, Jason P Hunt, MD, Shane Lloyd, MD, Ying J Hitchcock, MD, John R Weis, MD, Marcus M Monroe, MD

University of Utah


AHNS014

PD-L1 MAY SERVE AS A PROGNOSTIC BIOMARKER IN HPV-ASSOCIATED HEAD AND NECK CANCER PATIENTS

Immunotherapy and Other Adjuvant Treatments

Austin K Mattox1, Francesco Sabbatino2, Vincenzo Villani2, Soldano Ferrone2, William C Faquin3, Hang Lee4, Jill Brooks5, Armida Lefranc-Torres6, Derrick T Lin6, Lori J Wirth7, Christopher C McConkey8, Hisham Mehanna5, Sara I Pai2

1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, UK, 6Department of Otology and Laryngology, Massachusetts Eye and Ear Infirmary, Boston, MA, 7Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 8Warwick Clinical Trials Unit, University of Warwick, UK


AHNS015

THE ADDITION OF CHEMOTHERAPY TO THE ADJUVANT THERAPY OF LATE-STAGE SALIVARY SQUAMOUS CELL CARCINOMA IS ASSOCIATED WITH IMPROVED PATIENT SURVIVAL

Immunotherapy and Other Adjuvant Treatments

Shayan Cheraghlou, BA, Cheryl K Zogg, MSPH, MHS, Michael D Otremba, MD, Henry S Park, MD, MPH, Aarti Bhatia, MD, MPH, Saral Mehra, MD, MBA, Heather A Osborn, MD, Wendell G Yarbrough, MD, Benjamin L Judson, MD

Yale Medical School


AHNS017

DOES PERIOPERATIVE OXANDROLONE IMPROVE NUTRITIONAL STATUS IN PATIENTS WITH CACHEXIA RELATED TO HEAD AND NECK CARCINOMA?

Immunotherapy and Other Adjuvant Treatments

Angela M Osmolak, MD, Cristine Klatt-Lasso, MD, Amber Price, MD, Jose A Sanclement, MD, Greg A Krempl, MD

University of Oklahoma Health Science Center


AHNS018

LONGITUDINAL IMMUNE COMPLEXITY ANALYSIS USING 29-BIOMARKER MULTIPLEX IMMUNOHISTOCHEMISTRY IN PRIMARY AND RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA

Immunotherapy and Other Adjuvant Treatments

Grace L Banik, MD1, Rie Kawashima, DDS, PhD2, Tiziana Cotechini, PhD2, Sara I Pai, MD, PhD3, Armida LeFranc-Torres4, Derrick T Lin, MD4, Lori J Wirth, MD5, Daniel R Clayburgh, MD, PhD6, Lisa M Coussens, PhD7, Takahiro Tsujikawa, MD, PhD8

1Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, 2Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, 3Department of Surgery, Massachusetts General Hospital, Harvard University, 4Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, 5Department of Medicine, Massachusetts General Hospital, Harvard University, 6Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University; Knight Cancer Institute, Oregon Health and Science University, 7Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University; Knight Cancer Institute, Oregon Health and Science University, 8Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University; Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University; Knight Cancer Institute, Oregon Health and Science University; Department of Otolaryngology, Head and Neck Surgery, Kyoto Prefectural University of Medicine